Developmental Clinical Studies - Phase 1 studies on an analogue of peptide YY as a treatment for obesity

When humans eat, the gut releases a natural chemical called Peptide YY (PYY) that signals fullness and stops further eating. Researchers have now developed a synthetic version of this chemical, named Y242, and this study will test whether it is safe and tolerable for people to take as an obesity treatment. Obesity affects millions of people worldwide and is linked to serious health problems such as diabetes, heart disease, and joint damage. Current treatments are limited—many drugs have unpleasant side effects or only modest results, while surgery is invasive and not suitable for everyone. This research addresses the need for a new, non-surgical option that works with the body’s own appetite-control system. If Y242 proves safe in these early human trials, it could lead to a daily injection that reduces appetite and food intake without the side effects of existing medications. Such a treatment would give people a practical, biologically grounded tool for weight management, potentially lowering the burden of obesity-related diseases on individuals and the NHS. This is an early-stage safety study; much larger trials would be needed to confirm whether Y242 actually helps people lose weight over the long term.